NCT07843459 · Phase 1 · NOT YET RECRUITING
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
This early trial tests a Lilly drug called LY4560736 against a placebo in healthy adults and in people with Alzheimer's disease. Researchers are mainly checking safety and how the drug moves through the blood and brain, plus an Alzheimer's-related brain protein. It is a Phase 1 trial, the first step: not yet shown to work, and not approved.
You may qualify if
- Participants must meet eligibility criteria in the A1D-MC-ATMP screening protocol before entry into the treatment study.
- To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
- To qualify as Chinese for this study, all four of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
You're excluded if
- Have a condition that predisposes the participant to an infection.
- Have a current or recent acute, active infection.
- Have active tuberculosis (TB), have or have had latent TB.
- Are receiving therapeutic antibodies or expected to initiate treatment with therapeutic antibodies during the study.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-10-08